




evogene
REAL-WORLD INNOVATION



REAL-WORLD INNOVATION

AI-first driven discovery platform for multi-parameter small-molecule generation

August ,27 2026

FORWARD LOOKING STATEMENT

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent wars between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, as well as those additional factors described in greater detail in Evogene's Annual Report on Form 20-F and in other reports Evogene files with and furnishes to the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract or commitment relating thereto or to the securities of the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

EVOGENE PIONEERS REAL-WORLD INNOVATION

Using a proprietary generative AI engine, we generate novel and highly potent small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries



OUR STORY

PIONEERING IN PHARMA

Growing number of collaborations for a diverse pipeline of drug candidates



GEN AI ENGINE

ChemPass AI™ – computational engine for the generation & optimization of small molecules




REVOLUTIONIZING AG

Proven strategic collaborations driving our ag-chem pipeline



THE DISCOVERY & OPTIMIZATION CHALLENGE

GENERATE THE RIGHT CANDIDATES TO REACH THE MARKET



DIVERSE NOVEL CHEMICAL STRUCTURES & MULTI-PARAMETER **CHALLENGE**

The challenge - generate **diverse** small molecules with **novel** chemical structures that satisfy all **required parameters** defining the desired product, while proactively balancing multiple, often competing, criteria

CURRENT MAIN LIMITATIONS:


- Confined to a limited chemical space
- Lacks capability to perform multi-parameter optimization simultaneously



CHEMPASS AI™

BREAKING CHEMICAL SPACE LIMITATION & MULTI-PARAMETER CHALLENGE

NOVEL PRODUCT CANDIDATE



NOVEL CHEMICAL STRUCTURE, DRUG-LIKE, SYNTHESIZABLE MOLECULES

Our AI engine generates novel compounds that are synthesizable and active, while accessing unexplored chemical space and creating new IP opportunities



MULTI-PARAMETER OPTIMIZATION

Multiple-parameters optimized to project-specific chemical, biological, and physical constraints, increasing probability of success

CHEMOTYPE DIVERSITY - DE-RISKING DOWNSTREAM DEVELOPMENT

A broad and diverse scope of development candidates, that meet the defined product specifications


CHEMPASS AI™ - FOUR STEPS TO SUCCESS

Step 0

**AGENTIC BIOLOGICAL &
CHEMICAL TARGET ANALYSIS**
ABC MODULE™

BIOLOGICAL PROFILE

CHEMICAL PROFILE




Step 1

**HIT SCREENING
WITH POINTHIT™**

Utilizing deep learning to enhance
rapid screening of ultra-large
databases

VIRTUAL SCREEN RESULTS




POINTHIT

TRADITIONAL METHOD

Step 2

**HIT TO LEAD
WITH ACTIVESEARCH™**


DMTA* coupled with upgraded analog
search of ultra-large databases using
proprietary algorithms



Step 3

**LEAD OPTIMIZATION
WITH LEADOP GPT™**


Simultaneous optimization of multiple
parameters using generative AI



**REACHED MULTI-PARAMETER
OPTIMIZED nM ACTIVE NOVEL
COMPOUNDS**

RESULT


**EVOGENE
PRODUCT CANDIDATE**



OUR COMPETITIVE ADVANTAGE

ABC module™ - AGENTIC BIOLOGICAL & CHEMICAL ANALYSIS


- Biological Profile - MOA evaluation, experimental insights, specificity profile, structure ensembles
- Chemical Profile - Ligand properties, diversity mapping, curated experimental activities, ML models



Discovery risk profile –
Expert-vetted, data-backed target
dossiers

POINTHIT™ & ACTIVESEARCH™ - INTELLIGENCE: UNIQUE DATASET CREATION



- Both *POINTHIT™* & *ACTIVESEARCH™* explore ultra-large vendor libraries ~ **110B molecules**
- *POINTHIT™* utilizes virtual screening to generate a diverse range of chemotypes from the earliest stages of the discovery process
- *ACTIVESEARCH™* is an analogue search-engine coupled with QSAR to optimize DMTA cycles



Deep understanding of the biology
and chemistry underlying the
target product

LEADOP GPT™ - THE MAGIC: NOVEL MOLECULE GENERATION

- In-house built AI engine trained on curated **38B molecules database**
([Google Cloud collaboration #1](#))
- Generation of molecules that satisfy multiple project-specific parameters simultaneously
([Google Cloud collaboration #2](#))
- Precision generation of novel bioactive molecules tailored to target product criteria, eliminating inefficient traditional filtering



ALWAYS AT THE CUTTING EDGE OF TECHNOLOGY– LATEST ACHIEVEMENTS



AGENTS' INTEGRATION

"This expanded collaboration with Evogene demonstrates the power of integrating cutting-edge artificial intelligence into scientific research. By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows. This foundation accelerates the speed and precision of identifying small molecules, further cementing Evogene's role as a leader in next-generation molecular design for the pharmaceutical and agricultural industries"

BOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL



EXPANDED CHEMPASS AI™ VIRTUAL LIBRARY BY 200% TO 110 BILLION UNIQUE, ENUMERATED, VENDOR-ACCESSIBLE COMPOUNDS

Enabling AI-driven exploration of broader chemical space for novel pharmaceutical and agrochemical candidates.


110,000,000,000



NOVEL AI MODEL FOR PREDICTING ANTIFUNGAL POTENCY

Enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success at early discovery stages.

CHEMPASS AI™ - GENERATES CANDIDATES FOR COMMERCIAL SUCCESS




BUSINESS STRATEGY

CO-DEVELOPMENT - CAPTURE THE VALUE OF *CHEMPASS AI™*


Unlock the full potential of ChemPass AI™ through strategic collaborative partnerships, accelerating innovation in small-molecule drug and agrochemical development

PARTNERING WITH PHARMA, AG-CHEMICAL & BIOTECH COMPANIES that complement our capabilities, enabling groundbreaking innovations that benefit both parties



MAXIMUM POTENTIAL, MINIMUM RISK

CHEMPASS AI™ WORKFLOW



HARNESSING THE POWER OF CHEMPASS AI FOR REAL-WORLD INNOVATION

PHARMA DIVISION – Drugs



AG DIVISION* – Ag-Chemicals

systasy

Neutrophil-Derived
Inflammatory Diseases



Demyelination Disorders



Cardiovascular Diseases



Therapy Resistant
Lung Cancer



Metabolic Disease

UNDISCLOSED

Oncology Disease



Herbicides

INTERNAL PIPELINE

Wheat leaf Blotch
(Two targets)

INTERNAL PIPELINE

Undisclosed

OUR STORY

PIONEERING IN PHARMA

Growing number of collaborations for a diverse pipeline of drug candidates



GEN AI ENGINE

ChemPass AI™ – computational engine for the generation & optimization of small molecules





REVOLUTIONIZING AG

Proven strategic collaborations driving our ag-chem pipeline



GROWING OPPORTUNITY IN AI-DRUG DISCOVERY



**SMALL
MOLECULES**

Account for
58%¹
of total pharmaceutical market (\$1,344B)

AI-based candidates in pipeline
>60²
150% CAGR in last 3 years

Discovery market expected to reach
~\$190B³
by 2034



AI-FIRST COMPOUNDS UNDER DEVELOPMENT


The indicated data are for March 2025 *

Data includes both in-house and partner programs, data is NOT exhaustive, it reflects only information disclosed by companies on their websites.

 <https://www.biopharmatrend.com/>

 <https://www.TechLifeSci.com>

 @BiopharmaTrend



POTENTIAL COLLABORATORS & BUSINESS DEVELOPMENT STRATEGY

POTENTIAL PARTNERS	UNMET NEEDS	COMMON COLLABORATION PROFILE	TIMELINE
ACADEMIA/ SMALL BIOTECH	1. Rapid computational generation of molecules with high probability of success for novel targets 2. Composition of matter patents	A strategic partnership to co-develop a novel drug asset, generate shared IP and/or commercialization rights while accelerating the path to clinical development	Initiated end of 2025
MID-BIG SIZE BIOTECH/ MID SIZE PHARMA	1. Rapid computational generation of molecules with high probability of success for novel targets 2. Computational generation of novel chemotypes with improved patent positions and introduction of broad chemical diversity	Joint discovery and optimization of novel drug assets. Evogene will receive R&D and milestone-based payments, and royalties	Mid term (2027+)
GLOBAL PHARMA	1. Generation of novel chemotypes with improved patent positions and introduction of broad chemical diversity 2. Computational solutions for non-trivial targets	1. Joint discovery and optimization of novel drug assets. Evogene will receive R&D and milestone-based payments, and royalties 2. Evogene delivers a dedicated computational technology solution for a specific R&D challenge in exchange for upfront, R&D and milestone-based payments	Long term (2028+)

DIVERSIFIED DRUG DISCOVERY PIPELINE – (INITIATED Q4/25)


	INDICATION	PROGRAM	PREPROCESSING	HIT ID	HIT-TO-LEAD	LEAD OPTIMIZATION	PRE-CLINICAL	IND	PARTNER
COLLABORATIONS									
1	Oncology	EVG-O311	→						Undisclosed
2	Metabolism*	EVG-M410	→						
3	Immunology	EVG-I110	→						
4	Neurology	EVG-N210	→						
5	Oncology	EVG-O310	→						
6	Cardiology	EVG-C610	→						
INTERNAL PIPELINE									
1	Undisclosed	EVG-R510	→						

* Non-protein target

COLLABORATION WITH A LEADING ACADEMIC INSTITUTE (UNDISCLOSED)

NOVEL THERAPIES FOR BREAST CANCER TREATMENT AND LONGEVITY

- Target: novel key mechanism linked to cancer cell survival, migration and therapy resistance
- Global breast cancer therapy market is estimated at \$30B annually¹, with aggressive forms representing 10-15% of the cases², with an estimated market of \$5B³
- Combines *ChemPass AI*TM with expertise in spatial genomics and genome stability
- Designed to generate novel small-molecule candidates for aggressive form of breast cancer



BINDING SITE AND LIGAND OF TARGET

¹ <https://www.polarismarketresearch.com/industry-analysis/breast-cancer-therapy-market>

² <https://www.nationalbreastcancer.org/triple-negative-breast-cancer>



³ <https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market>

POINTHIT™ - SUPERIOR HIT RATES OF HIGHLY POTENT MOLECULES

42 molecules identified with outstanding results*

- 43% of tested considered candidate inhibitors
- 19% of tested compounds have nM efficacy

"We used to screen thousands of compounds to get hits, with ChemPass AI this is not required. Out of 42 compounds, 18 (43%) are inhibitors, and 8 (19%) are potential candidates." PI




* Intermediate analysis

COLLABORATION WITH PROF. EHUD GAZIT, TAU, TEL-AVIV, ISRAEL

NOVEL THERAPEUTIC MODALITY FOR METABOLIC DISEASES



- Target: molecular self-assembly metabolites that underlie metabolic conditions
- Addressable Gout therapeutics market is evaluated at ~\$3B*
- Combines ChemPass AI™ with unique biological research in molecular self-assembly biology
- Creates opportunities for novel therapeutics addressing the cause of disease rather than symptomatic treatment




SCANNING ELECTRON MICROSCOPY OF CRYSTALS
FORMED BY THE SELF-ASSEMBLY OF A METABOLITE

* Costa-Bauza, A., & Grases, F. (2023). Biomolecules, 13(12), 1769.

"We are excited to join forces with Evogene in this groundbreaking endeavor. By integrating our fundamental understanding of molecular self-assembly with Evogene's cutting-edge AI-driven drug design platform, we have a unique opportunity to develop novel therapeutics that specifically target these pathological processes and ultimately improve treatment for patients."

COLLABORATION WITH PROF. EHUD GAZIT, TAU, TEL-AVIV, ISRAEL

NOVEL THERAPEUTIC MODALITY FOR METABOLIC DISEASES – *CHEMPASS AI™* RESULTS



INTERMEDIATE ANALYSIS OF INITIAL 15 MOLECULES

- 33% of tested compounds reach activity threshold
- 2 molecules outperformed positive control

NEXT STEP

- Ongoing testing of additional molecules for hit identification

OUR STORY

PIONEERING IN PHARMA

Growing number of collaborations for diverse drug targets



GEN AI ENGINE

ChemPass AI™ – computational engine for the generation & optimization of small molecules



REVOLUTIONIZING AG


Proven strategic collaborations driving our ag-chem pipeline



~\$88B GROWING MARKET WITH PLENTY OF ROOM FOR INNOVATION

UNMET NEEDS

- 1** Increase of pest resistance
& regulatory requirements
- 2** Urgent need for new
Modes of Action (MoAs)
- 3** Decreased rate in discovery
of new pesticides due to lack
of innovation



\$47.3B
BROAD SPECTRUM
HERBICIDES¹

\$20.08B
FUNGICIDES FOR
MAJOR DISEASES²

\$24.3B
BROAD SPECTRUM
INSECTICIDES³

LEADING CROP PROTECTION COMPANIES

 **BASF**



The FMC logo consists of the letters "FMC" in a bold, red, sans-serif font.

The Syngenta logo features the word "syngenta" in a blue, lowercase, sans-serif font, with a green leaf icon above the letter "y".



The Gowan logo features the word "Gowan" in a blue, sans-serif font, with a small green triangle above the letter "a".

The Nufarm logo features the word "nufarm" in a green, lowercase, sans-serif font, with a small green leaf icon above the letter "n".





The Kureha logo features the word "KUREHA" in a blue, uppercase, sans-serif font, with a green arrow pointing to the right below the letters.



NIPPON SODA CO.,LTD.

POTENTIAL DISCOVERY AND OUTLICENSE PARTNERS

CURRENT CROP PROTECTION PIPELINE


	PROGRAM	TARGET	PREPROCESSING	HIT ID	HIT-TO-LEAD	LEAD OPTIMIZATION	SAFETY & ENVIRONMENTAL	FIELD TESTING	PARTNER
	COLLABORATIONS								
1	Herbicide	APCO-12	Stage confidential						
	INTERNAL PIPELINE								
1	Wheat leaf blotch	APTF1							
2	Wheat leaf blotch	APTF4							
3	Fungicide/ Undisclosed	APTF9							

INTERNAL PIPELINE WHEAT BLOTCH

DISRUPTING A \$1.2B PROBLEM AT RECORD SPEED

- 70% of EU fungicide usage in wheat is for Wheat Blotch
- EU market alone >\$1.2B annually
- Widespread resistance to current top products ('Strobilurins') with 2025 sales of \$4.76B¹


APTF-1 PRESENTS STRONG POTENTIAL FOR REAL-WORLD INNOVATION



DETACHED LEAF ASSAY

- Shows clear concentration-dependent antifungal efficacy
- Ongoing optimization to enhance potency
- 18 months from target to optimized hit

END-TO-END PROCESS – NOVEL, HIGHLY POTENT, OPTIMIZED MOLECULES



EVOGENE – LOOKING FORWARD

PHARMA DIVISION – DRUGS

- Progress in existing pipeline
- New collaborations with biotech companies and academic institutions
- Building relationships with pharmaceutical companies
- Evaluation of projects for an internal pipeline



AG DIVISION* – AG-CHEMICALS

- Progress in existing pipeline
- New collaborations with ag-chem companies
- Evaluation of projects for expanding internal pipeline



ADDITIONAL TECH COLLABORATIONS TO MAINTAIN OUR COMPETITIVE ADVANTAGE

**NOVEL, DRUG-LIKE,
SYNTHESIZABLE MOLECULES**

**MULTI-PARAMETER
OPTIMIZATION**

**DE-RISKING DOWNSTREAM
DEVELOPMENT**

We generate highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries

ev^ogene
Real-world innovation



PIONEERING IN PHARMA

Growing number of collaborations addressing diverse drug targets for the benefit of human health



REVOLUTIONIZING AG

Proven impact in Agriculture. Computational chemistry drives real-world agricultural impact

**GENERATING REAL-WORLD
INNOVATION**

evogene



Creating

**REAL-WORLD
INNOVATION**

for a better future